71. RIG-I detects infection with live Listeria by sensing secreted bacterial nucleic acids.
Abdullah Z, Schlee M, Roth S, Mraheil MA, Barchet W, Böttcher J, Hain T, Geiger S, Hayakawa Y, Fritz JH, Civril F, Hopfner KP, Kurts C, Ruland J, Hartmann G, Chakraborty T, Knolle PA
EMBO J. 2012 Nov 5.
PMID: 23064150 [PubMed - in process]
72. The MET Oncogene as a Therapeutical Target in Cancer Invasive Growth.
Luraghi P, Schelter F, Krüger A, Boccaccio C
Front Pharmacol. 2012 .
PMID: 22973229
73. NLRP3 inflammasome activity is negatively controlled by miR-223.
Bauernfeind F, Rieger A, Schildberg FA, Knolle PA, Schmid-Burgk JL, Hornung V
J Immunol. 2012 Oct 15.
PMID: 22984082 [PubMed - in process]
74. Foxp3+ regulatory T cells protect the liver from immune damage and compromise virus control during acute experimental hepatitis B virus infection in mice.
Stross L, Günther J, Gasteiger G, Asen T, Graf S, Aichler M, Esposito I, Busch DH, Knolle P, Sparwasser T, Protzer U
Hepatology. 2012 Sep .
PMID: 22487943 [PubMed - in process]
75. TNF-induced target cell killing by CTL activated through cross-presentation.
Wohlleber D, Kashkar H, Gärtner K, Frings MK, Odenthal M, Hegenbarth S, Börner C, Arnold B, Hämmerling G, Nieswandt B, van Rooijen N, Limmer A, Cederbrant K, Heikenwalder M, Pasparakis M, Protzer U, Dienes HP, Kurts C, Krönke M, Knolle PA
Cell Rep. 2012 Sep 27.
PMID: 22939982 [PubMed - in process]
76. Rab31 expression levels modulate tumor-relevant characteristics of breast cancer cells.
Grismayer B, Sölch S, Seubert B, Kirchner T, Schäfer S, Baretton G, Schmitt M, Luther T, Krüger A, Kotzsch M, Magdolen V
Mol Cancer. 2012 .
PMID: 22920728
77. The liver's imprint on CD8⁺ T cell priming.
Knolle PA
J Hepatol. 2012 Oct .
PMID: 22814455 [PubMed - in process]
78. On the Pro-Metastatic Stress Response to Cancer Therapies: Evidence for a Positive Co-Operation between TIMP-1, HIF-1α, and miR-210.
Cui H, Grosso S, Schelter F, Mari B, Krüger A
Front Pharmacol. 2012 .
PMID: 22807917
79. Differential Impact of Cysteine Cathepsins on Genetic Mouse Models of De novo Carcinogenesis: Cathepsin B as Emerging Therapeutic Target.
Reinheckel T, Peters C, Krüger A, Turk B, Vasiljeva O
Front Pharmacol. 2012 .
PMID: 22798952
80. A nebulized gelatin nanoparticle-based CpG formulation is effective in immunotherapy of allergic horses.
Klier J, Fuchs S, May A, Schillinger U, Plank C, Winter G, Coester C, Gehlen H
Pharm Res. 2012 Jun .
PMID: 22302522 [PubMed - in process]